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Background: Objective of the present study was to examine the association between adiponectin and hepatic
steatosis, and other biochemical and anthropometric parameters in healthy subjects.
Results: A total of 1349 subjects (age 18–65 years) underwent ultrasound examination of the liver. Mean adiponectin
concentration for the study collective was 11.35 ± 6.28 μg/mL. The following parameters were assessed for their
association with adiponectin: body-mass index (BMI); age; sex; arterial blood pressure; nicotine use; alcohol
consumption; physical activity; metabolic syndrome; total, low-density lipoprotein (LDL) and high-density lipoprotein
(HDL) cholesterol; triglycerides; aspartate aminotransferase (AST); alanine aminotransferase (ALT); γ-glutamyltransferase
(GGT); alkaline phosphatase (AP); C-reactive protein (CRP); insulin sensitivity according to the Homeostasis Model
Assessment (HOMA); random blood glucose; and the degree of steatosis of the liver. The numerical differences in the
variables influencing adiponectin returned in the descriptive analysis were confirmed at bivariate analysis for BMI, ALT,
AST, GGT, AP, total and HDL cholesterol, triglycerides, CRP, arterial blood pressure, metabolic syndrome, nicotine use
and alcohol consumption. The logistic regression of the multivariate analysis showed that male sex, hepatic steatosis,
BMI, metabolic syndrome, tobacco smoking and CRP correlate negatively with adiponectin, while age, moderate
alcohol consumption and HDL cholesterol exhibit a positive association.
Conclusions: The results of the present study confirm the findings of previous research. Adiponectin correlates
negatively with cardiometabolic risk factors and is an independent indicator for non-alcoholic fatty liver disease
(NAFLD).
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Over the past several years, non-alcoholic fatty liver dis-
ease (NAFLD) has gained increasing importance, both as
a clinical entity and as a focus of research [1]. NAFLD is
characterized by an increased accumulation of fat in the
hepatocytes in the absence of excessive alcohol con-
sumption [2]. Its prevalence worldwide is estimated in
the range of 20-30%. NAFLD includes both non-alcohol
fatty liver (NAFL), characterized by a simple increase in* Correspondence: Wolfgang.Kratzer@uniklinik-ulm.de
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distribution, and reproduction in any mediumthe fat content of the liver, and non-alcoholic steatohepa-
titis (NASH) with increased fat content and inflammatory
infiltrates. About 10-20% of patients with NAFL develop
NASH, which may ultimately lead to cirrhosis of the liver
and to hepatocellular carcinoma (HCC) [3-5].
While NAFLD is closely associated with obesity, type
2 diabetes mellitus and coronary artery disease (CAD), it
may occur in the absence of type 2 diabetes and CAD
[6,7]. The increased fat content of the liver correlates
positively with the insulin resistance that characterizes
metabolic syndrome [8]: hence, NAFLD is often consid-
ered an hepatic manifestation of metabolic syndrome
[9]. It remains unclear, however, whether insulin resistanceCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Table 1 The concentration of adiponectin in 1,349
healthy subjects
N Adiponectin (μg/ml) Mean ± SD
Sex
Females 733 13,87 ± 6,77
Males 616 8,34 ± 3,89
Age (years)
18-30 274 10,77 ±,44
31-40 400 10,97 ± 6,08
41-50 312 11,22 ± 6,34
51-65 363 12,30 ± 6,91
Hepatic steatosis
Grad 0 1016 12,02 ± 6,44
Grad 1 153 10,27 ± 6,07
Grad 2/3 180 8,47 ± 4,27
Body Mass Index (kg/m2)
<25 704 12,65 ± 6,64
25-30 437 10,14 ± 5,61
>30 208 9,48 ± 5,30
Hypertension
No 1174 11,48 ± 6,29
Yes 164 10,59 ± 6,18
Unknown 11 8,30 ± 4,96
Metabolic syndrome
No 1296 11,51 ± 6,31
Yes 53 7,38 ± 3,64
Tobacco smoking
No 672 12,16 ± 6,76
Yes 385 10,34 ± 5,85
Former smoker 292 10,81 ± 5,35
Alcohol
Ex-drinker 40 9,78 ± 5,51
0 g 509 11,32 ± 6,20
1-20g/Tag 671 11,89 ± 6,65
21-40g/Tag 129 9,14 ± 3,79
Physical exercise
No 523 11,19 ± 6,52
Yes 826 11,44 ± 6,12
SD = standard deviation.
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whether an increased fat content of the liver precedes
the development of insulin resistance or causes insu-
lin resistance per se [10]. It is known that adiponectin,
a peptide hormone released from adipose tissue af-
fects both the fat content of the liver and the develop-
ment of NAFLD [11].
Unlike most adipose tissue hormones, adiponectin
shows decreased concentrations in obesity and corre-
lates negatively with both cardiometabolic risk factors
and with the fat content of the liver [12,13]. Adipo-
nectin concentrations are 20-60% lower in patients
with NAFLD than in healthy persons [8]. There is evi-
dence in the literature that adiponectin at sufficiently
high concentrations may protect against the development
of NAFL [14].
Objective of the present study was to analyze the asso-
ciation between adiponectin and cardiometabolic risk
factors, and with sonographically diagnosed hepatic stea-
tosis in a healthy population of a small German town.
Results
Descriptive analysis
The study collective consisted of 1,349 subjects (733
females, 54.3%; 616 males, 45.7%; mean age, 41.3 ±
12.5 years). Among all subjects, 24.7% exhibited sono-
graphic evidence of hepatic steatosis, 47.8% were over-
weight, 12.2% had a history of hypertension, 3.9% fulfilled
the (modified) criteria for metabolic syndrome, 50.1% were
current or former smokers, 87.3% reported no or very low
consumption of alcohol, and 61.2% described engaging in
physical exercise.
The mean plasma concentration of adiponectin in all
1,349 study subjects was 11.35 ± 6.28 μg/mL. The mean
adiponectin concentrations of subjects broken down by
age, degree of hepatic steatosis, BMI, metabolic syndrome,
alcohol consumption and physical exercise are given in
Table 1. Table 2 gives mean adiponectin concentrations of
subjects broken down according to laboratory parameters
that were within, above or below the respective reference
ranges.
Bivariate analysis
There was a statistically significant negative correlation
between the adiponectin concentration and BMI. The
hepatic function (ALT, AST, GGT) and cholestasis pa-
rameters (AP) also correlated negatively with adiponec-
tin. Among the lipids, triglycerides showed a negative
correlation, while total cholesterol showed a weak posi-
tive correlation and HDL cholesterol a narrowly positive
correlation. LDL cholesterol showed a negative correl-
ation without, however, attaining statistical significance.
Random blood glucose and insulin sensitivity (HOMA)
also showed a negative correlation with adiponectinconcentrations, though likewise failing to achieve statistical
significance (Table 3).
Hypertension, metabolic syndrome, hepatic steatosis
and tobacco use showed a negative correlation with adi-
ponectin (p < 0.0001). There was a positive correlation
with age and alcohol consumption (p < 0.0001). There
was no clear correlation between physical exercise and
the adiponectin concentration (p < 0.3285).
Table 2 Adiponectin concentration broken down
according to laboratory parameters
N Adiponectin (μg/ml) Mean ± SD
ALT
Normal 1172 11.68 ± 6.38
Elevated 177 9.13 ± 5.05
AST
Normal 1319 11.36 ± 6.22
Elevated 30 10.55 ± 8.32
GGT
Normal 1196 11.34 ± 6.22
Elevated 114 11.02 ± 7.08
Reduced 39 12.55 ± 5.36
AP
Normal 1167 11.03 ± 6.27
Elevated 7 13.98 ± 7.43
Reduced 175 13.38 ± 5.91
Triglycerides
Normal 952 12.25 ± 6.65
Increased 397 9.19 ± 4.63
Cholesterol
Normal 500 10.98 ± 6.58
Increased 849 11.56 ± 6.09
HDL-Cholesterol
Normal 1050 10.22 ± 5.39
Increased 299 15.32 ± 7.46
LDL-Cholesterol
Normal 538 11.58 ± 6.49
Erhöht 811 11.19 ± 6.13
Random Glucose
Normal 1305 11.32 ± 6.27
Elevated 37 11.70 ± 5.72
Reduced 7 14.21 ± 10.16
CRP
Normal 1192 11.48 ± 6.30
Elevated 157 10.34 ± 6.03
HOMA
Normal 211 10.49 ± 6.46
Elevated 33 9.20 ± 5.66
ALT = Alanine aminotransferase, AP = Alkaline phosphatase, AST = Aspartate
aminotransferase, CRP = C-reactive protein, GGT = γ-glutamyl-transferase,
HDL = High Density Lipoprotein, HOMA = Homeostasis Model Assessment,
LDL = Low Density Lipoprotein Random-Glucose = Glucose independent of
meal times; HOMA = Homeostasis Model Assessment, SD = standard deviation.
Table 3 Correlation coefficient (r) between the
adiponectin concentration and different laboratory
parameters, and BMI
r p
ALT - 0.325 <0.0001
AST - 0.173 <0.0001
GGT - 0.311 <0.0001
AP - 0.176 <0.0001
Cholesterol 0.062 0.0235
LDL-Cholesterol - 0.050 0.0675
HDL-Cholesterol 0.521 <0.0001
Triglycerides - 0.310 <0.0001
Random blood glucose - 0.040 0.1390
HOMA - 0.103 0.1080
CRP - 0.068 0.0128
BMI - 0.292 <0.0001
ALT = Alanine aminotransferase, AP = Alkaline phosphatase, AST = Aspartate
aminotransferase, BMI = Body-Mass Index, CRP = C-Reactive Protein, GGT = γ-
glutamyl-transferase, HDL = High Density Lipoprotein, HOMA = Homeostasis
Model Assessment, LDL = Low Density Lipoprotein Random-Glucose = Glucose
independent of meal times; HOMA = Homeostasis Model Assessment, SD =
standard deviation; Random glucose = Glucose independent of time of day.
Table 4 Association of the adiponectin concentration
with various parameters in the multivariate regression
analysis
b p
Male sex - 0.318 <.0001
Hepatic steatosis - 0.064 0.0475
BMI - 0.010 0.0011
Age 0.004 <.0001
Triglycerides - 0.024 0.1242
HDL Cholesterol 0.356 <.0001
CRP - 0.004 0.0434
Metabolic syndrome - 0.128 0.0434
Tobacco smoking - 0.065 0.0117
Alcohol consumption (0-20 g/d) 0.052 0.0327
Alcohol consumption (20-40 g/d) 0.093 0.0380
BMI = Body-mass index, CRP = C-reaktives
Protein, HDL = High-Density-Lipoprotein.
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Multivariate analysis demonstrated a negative correlation
between the adiponectin concentration and the factors
male sex, hepatic steatosis, BMI, metabolic syndromeand tobacco smoking. By comparison, age correlated
positively with the adiponectin concentration. While HDL-
cholesterol exhibited a positive correlation with adipo-
nectin, the correlation with CRP was negative (Table 4).
Discussion
The present study examined the largest collective of
healthy subjects assessed to date for an association be-
tween sonographically diagnosed hepatic steatosis and
plasma adiponectin concentrations. Sonographic evidence
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The multivariate analysis of our data shows a negative cor-
relation between adiponectin and hepatic steatosis. Break-
ing down study subjects according to sonographically
determined hepatic fat content into groups with grade 0, 1
and 2/3 steatosis, it was observed that adiponectin concen-
trations decline inversely to the degree of steatosis.
This observation corresponds to findings of Pisto et al.
in which an increase in hepatic fat content, estimated by
sonographic assessment of brightness into levels 0, 1
and 2, was associated with a decrease in adiponectin
concentrations [15]. The results of that study and ours
are in good agreement even though the earlier study
measured comparatively higher adiponectin concentra-
tions. These differences in adiponectin concentrations
may possibly be due to the different age distribution of
the two study collectives as since the concentration of
adiponectin in the blood increases with age [16].
In our study collective, the mean adiponectin concen-
tration was significantly higher in women than in men.
This known difference between the sexes emerges at pu-
berty and efforts have been made to explain it on the
basis of differences in androgen levels [16,17]. Experi-
mental studies, however, have failed to demonstrate a
direct influence of androgens on adiponectin concentra-
tions. It has been postulated that the sex hormones
regulate as yet unknown factors that, in turn, affect the
adiponectin concentration [18].
In our study collective, BMI correlates negatively with
the adiponectin concentration. These results correspond
with those of earlier studies [19]. However, it has also
been shown that adiponectin is not associated with the
BMI or subcutaneous adipose tissue but correlates signifi-
cantly and negatively with the mass of visceral adipose
tissue [20]. It was furthermore shown that adiponectin
concentrations correlated negatively with the mass of vis-
ceral fat but positively with the mass of subcutaneous fat
[21]. Contradictory study findings regarding the associ-
ation between adiponectin and BMI are possibly the result
of the different composition of the respective study collec-
tives with respect to the degree of overweight and the rela-
tive proportions of subcutaneous and visceral adipose
tissue [21].
A total of 61.2% of the subjects in our study popula-
tion were physically active (by self-report). Those who
engaged in physical exercise showed higher mean adipo-
nectin concentrations than did subjects who did not
report being physically active. Multivariate analysis, how-
ever, failed to demonstrate a statistically significant dif-
ference in adiponectin levels between these groups. It is
possible that the intensity of physical exercise was too
low or the difference in physical activity between the
groups was too small. A review of the literature reveals
that participation in a physical exercise program isassociated with an increase in adiponectin concentrations
in the blood [22,23] and that the fat content and histo-
logical signs of inflammation in the liver are reduced [24].
The association between adiponectin and cardiovascular
risk factors and NAFLD were described. There was a cor-
relation between adiponectin and steatosis hepatis, and
there was a correlation between adiponectin and hyper-
tension. The association between fatty liver and hyperten-
sion is well known [25]. Further NAFLD with or without
increased ALT levels is associated with progression of
blood pressure over time and incident hypertension
[26,27]. In our study out of 1349 healthy subjects only 80
subjects had NAFLD. Because of the low portion of sub-
jects with hypertension the relationship between hyperten-
sion and hepatic steatosis was not analyzed in detail.
In our study, adiponectin concentrations correlated
negatively with triglycerides and positively with HDL-
cholesterol. These observations correspond to the find-
ings of other studies [28]. The action of adiponectin on
triglyceride concentrations is ascribed to an increase in
fatty acid oxidation via sequential activation of AMPK,
p38 MAPK and PPAR-α [29]. A direct action of adipo-
nectin on the catabolism of apoprotein A-I explains
the positive correlation between adiponectin and HDL-
cholesterol [30].
Only 3.9% of subjects participating in the present
study fulfilled the minimum number of criteria required
for diagnosing metabolic syndrome. The low prevalence
of metabolic syndrome is most likely due to the fact that
diabetics, who very frequently suffer from metabolic syn-
drome, were not included in the study [31].
Adiponectin was negatively associated with plasma
CRP concentrations. This association confirms observa-
tions reported by other authors [28]. Anti-inflammatory
properties have also been described for adiponectin and
this may be important in the progression of NAFL to
NASH [32,33]. Evidence from animal experiments sug-
gests that adiponectin attenuates signs of inflammation
and may protect against the development of NASH [34].
It has recently been shown in one prospective study and
in another longitudinal study that a high adiponectin
concentration protects against development of metabolic
syndrome [35,36].
In the present study, multivariate analysis showed a
significant positive association between adiponectin and
moderate alcohol consumption. Earlier randomized
cross-over and intervention studies had also reported
that moderate alcohol consumption was associated with
an increase in adiponectin levels [37,38]. In contrast to the
findings of studies conducted in Europe, cross-sectional
studies from Japan found a negative association between
adiponectin and alcohol consumption [39]. These diver-
gent findings may have an ethnic basis or related to sub-
jects’ environment.
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in those subjects classified as tobacco smokers than in
non-smokers. This corresponds to the finding that, in
non-smokers, acute exposition to tobacco smoke results
in a decline in adiponectin levels within 12 hours and
that smokers who abstain from smoking exhibit an in-
crease in adiponectin concentrations within two months
[40,41]. The reduced adiponectin level in smokers may
be explained by an inhibitory effect of nicotine on the
expression of adiponectin from fat cells [40]. The role of
genetic background in the association between adipo-
nectin and fatty liver was not addressed in this study.
However, it is known from the literature that adiponec-
tin gene rs266729 polymorphism increases the risk of
NAFLD [42]. Also the transcription factor sterol regula-
tory element-binding protein-1 c (SREBP-1c) may con-
tribute to the development of NAFLD. The SREBP-1c
gene rs11868035 polymorphism is associated with a high
risk of NAFLD [43]. Further genetic variants in the Patatin
like phospholipase-3 (PNPLA3) gene are associated with
increased risk of nonalcoholic fatty liver disease [44,45].
PNPLA3 rs738409 (I148M) genotypes may represent a
genetic determinant of serum adiponectin concentrations
and may be involved in mediating the susceptibility of liver
steatosis [46].
Hypertension and NAFLD both are components of the
metabolic syndrome and are associated with low levels
of adiponectin. Increased expression of adiponectin
or administration of recombinant adiponectin corrects
hypertension and NAFLD. This implies a therapeutic
potential of adiponectin [47]. Further low levels of adi-
ponectin are found in subjects with diabetes and coron-
ary artery disease [48]. Raising adiponectin levels or
enhancing activity of adiponectin receptors may attenu-
ate the components of the metabolic syndrome and may
improve the management of diabetes and of cardiovascu-
lar diseases [49].
The main strength of the present study is that it exam-
ined a healthy population under normal domestic condi-
tions using standardized methods. One weakness is that
only 60% of the selected population actually participated
in the study. This is due in part to the exclusion of sub-
jects with liver diseases and diabetes mellitus, as well as
subjects with incomplete documentation. Other draw-
backs were that the study is a cross-sectional study with
singular observations and that collection of personal
data were based on questionnaires. The study was aimed
at the association between adiponectin and NAFLD. In
the population the portion of participants with hyperten-
sion and metabolic syndrome were relatively low. Larger
studies with patients with the metabolic syndrome or
with hypertension are necessary to confirm the observa-
tions made in this population based study. Another weak-
ness of the present study is that the genetic background ofthe association of adiponectin with steatosis and hyper-
tension is not addressed. The relationship between
normotensive and hypertensive blood pressure values
and adiponectin concentrations was established in our
study. Previously, the glycoprotein PI(A2) allele was
identified as an risk factor for stroke in high-risk hyper-
tensive patients [50]. In the present study, we did not
investigate glycoprotein IIIa PI(A1/A2) polymorphism
in subjects with hypertension. It is possible that the PI
(A1/A2) polymorphism is important for development of
both hypertension and NAFLD. In patients with CAD,
for instance, the presence of the PIA2 allele was associ-
ated with a higher risk of cardiovascular events, while,
in hypertensive patients with cerebrovascular events,
the PIA2 allele increased the risk of stroke [51]. As
hypertension is the most frequent component of the
metabolic syndrome, the genetics underlying the regula-
tion of blood pressure may be crucial for the devel-
opment of cardiovascular and cerebrovascular events.
Understanding the underlying pathogenetic mecha-
nisms of hypertension may lead to more effective strat-
egies of treatment. Recently, it has been shown that the
CaMKIIV gene is involved in regulation of vascular tone
and blood pressure. In hypertensive patients, a CaMKIV
polymorphism identifies a subset of patients with higher
blood pressure values [52]. It may be assumed that the
CaMKIV gene deletion not only induces hypertension and
cardiovascular disease but also NAFLD. Further limita-
tions of the study include the fact that liver biopsies were
not performed to confirm the sonographic diagnosis of
NAFLD and data on alcohol and nicotine use, as well as
physical activity, were self-reported by study subjects. In
addition, for logistical reasons, blood samples were ob-
tained throughout the day meaning that dietary parame-
ters should be considered critically. In this respect
limitation is related to the definition of the metabolic
syndrome, that divergent from the NCEP ATP III defin-
ition, random blood glucose instead of fasting blood glu-
cose was used as one out of three criteria required.
Conclusion
The present study investigated factors associated with
adiponectin in a collective of healthy subjects examined
by means of diagnostic ultrasound.
The numerical differences in the variables influencing
adiponectin returned in the descriptive analysis were
confirmed at bivariate analysis for BMI, ALT, AST, GGT,
AP, total and HDL cholesterol, triglycerides, CRP, arterial
blood pressure, metabolic syndrome, nicotine use and al-
cohol consumption.
Male sex, BMI, triglycerides, CRP, tobacco smoking,
metabolic syndrome and non-alcoholic fatty liver correlate
negatively with adiponectin concentrations. There was a
positive association between adiponectin concentrations
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cholesterol levels. These findings underscore the import-
ance of adiponectin as a biomarker for cardiometabolic risk




Four-thousand persons were selected randomly from the
registered population of a southern German city (total
population, 12,475). Of these, a total of 2,445 persons
participated in the study. Subjects completed a stan-
dardized questionnaire regarding personal data, lifestyle
habits and medical history. Subjects underwent ultrasound
examination to determine the fat content of the liver [53].
Subjects with history of liver diseases, those treated with
antidiabetic agents, and those with incomplete data were
excluded from the study (Figure 1). Of the remaining 1,349
subjects, 54.3% were women.
The study was conducted in conformity with the prin-
ciples of the Helsinki Declaration and Good Clinical
Practice recommendations and was approved by the
Ethics Commission of the State Medical Council of
Baden-Württemberg (No. 133–02, 24 September 2002).
All study participants provided their informed written
consent.
Questionnaire
Each subject received a questionnaire that was com-
pleted under the supervision of a trained interviewer.
Subjects provided information on their date of birth,
sex, body height, body weight, social history, medical
history, alcohol consumption, smoking habits and phys-
ical activity. In order to validate the results multiple
crosschecked questions on the same topic were ad-
dressed to the participants. The interview was partially
based on validated instruments from other, predominantlyFigure 1 Flow of the subjects across the study.cardiovascular, studies (i. e. alcohol questions from the
MONICA Study). Further details on the questionnaire has
been published in a previous work of the EMIL-study
group [53].
Laboratory studies
Blood samples for laboratory examinations were obtained
by means of phlebotomy of a cubital vein. Routine la-
boratory testing was performed in the Department of
Clinical Chemistry of the University Hospital of Ulm
using the Dimension XL unit (Dade Behring Inc, Newark,
DE, USA) in accordance with guidelines of the Inter-
national Federation of Clinical Chemistry and Laboratory
Medicine (IFCC). Adiponectin concentrations were deter-
mined radioimmunologically using the Human Adiponec-
tin RIA Kit (Catalog HADP-61HK, Biotrend Chemikalien
GmbH, Cologne, Germany). LDL cholesterol concentra-
tions were calculated using the Friedewald formula. The
diagnosis of metabolic syndrome was made in accord-
ance with the National Cholesterol Education Program
Adult Treatment Panel III criteria (NCEP-ATP III) [54]
with the exception that random blood glucose levels were
substituted for the fasting glucose concentration required
by NCEP-ATP III.
Ultrasound
All subjects underwent ultrasound examination of the
liver. Examinations were performed by specially trained
examiners using four identical HDI 5000 ultrasound
scanners (ATL Ultrasound, Philips Medical Systems,
Bothell, WA, USA) under the supervision of an experi-
enced sonographer. Findings were documented using a
standardized recording form. Based on a sonographic com-
parison of the hepatic and renal parenchyma, assessment
of dorsal echo attenuation by the liver, the visualization of
the diaphragm and the hepatic vessels, the degree of hep-
atic steatosis was classified as “none” (grade 0), or as “mild”
(grade 1), “moderate” (grade 2), or “severe” (grade 3) fatty
liver disease [55]. The sonographic grading of hepatic stea-
tosis into severity grades 0 to 3 has been shown to be clin-
ically reliable and useful [56].
Statistical analysis
Statistical calculations were performed using the SAS
statistical software package (version 9.2; SAS Institute,
Cary, NC, USA). Constant laboratory values were di-
vided into classes with respect to their reference ranges.
Historical data were divided according to reasonable cri-
teria. Data were first analyzed descriptively. Categorical
variables were represented with absolute and relative fre-
quencies. Mean and standard deviation were determined
for constant variables.
The correlation of adiponectin with quantitative vari-
ables was calculated using the Spearman rank correlation.
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were used for qualitative variables. Multivariate linear
regression was used to test the influence of individual pa-
rameters on adiponectin concentrations. Adiponectin con-
centrations were log transformed in order to achieve a
normal distribution. All tests were two-tailed. Statistical
significance was established at α = 5%.
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